Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm, Phase 1/2 Study of SNX-5422 in Subjects With Selected HER2 Positive Cancers

Trial Profile

A Single Arm, Phase 1/2 Study of SNX-5422 in Subjects With Selected HER2 Positive Cancers

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 11 Feb 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SNX 5422 (Primary)
  • Indications Advanced breast cancer; Non-small cell lung cancer; Oesophageal cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Sponsors Esanex
  • Most Recent Events

    • 20 Apr 2015 Planned End Date changed from 1 May 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
    • 20 Apr 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 21 Aug 2013 New source identified and integrated (Memorial Sloan-Kettering Cancer Center: 13-112).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top